Linked Life Data

8828955

Source:http://linkedlifedata.com/resource/pubmed/id/8828955

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1996-12-10
pubmed:abstractText
In this paper we review the results of six studies, published between 1985 and 1993, which report on immunoglobulin treatment in children with idiopathic diabetes mellitus (IDDM). A total of 77 children with newly diagnosed IDDM were infused with high dose gammaglobulin, while 56 patients were not infused and served as controls. Clinical outcome as judged by the rate of induction and duration of remission, insulin requirement, metabolic control (HbAlc) and C-peptide were determined. Side effects of treatment with 0.4 g gammaglobulin/kg bw/day were minimal, and were remarkable with 2 g/kg bw/day as single doses. No significant differences between the treated and control IDDM children were observed in metabolic control or C-peptide release, while the insulin requirement was significantly less in 2 studies during immunoglobulin therapy. In all 6 studies a subgroup of patients showed some benefit from treatment, with higher rates and longer durations of remissions and preserved C-peptide release. However, no guidelines can be offered at this point for those patients who may possibly benefit from immunoglobulin therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0392-856X
pubmed:author
pubmed:issnType
Print
pubmed:volume
14 Suppl 15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S99-102
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:articleTitle
Immunoglobulins in children with autoimmune diabetes mellitus.
pubmed:affiliation
Children's Hospital, University of Ulm, Germany.
pubmed:publicationType
Journal Article, Review